Anlageziel

The Sub-Fund’s objective is to achieve returns that are greater than, and relatively independent of, those generated by the Healthcare securities markets over the economic cycle. There is however no guarantee that this objective will be achieved. The investment policy of the Sub-Fund is to invest principally (i.e. min 50.1%) of the Sub-Fund’s net assets in publicly listed equity investments in innovative biotechnology and healthcare companies. The Sub-Fund has a global mandate with a focus on Europe and the US. The Manager uses a bottom-up stock selection process with the Fund typically containing 25-50 companies in a diversified portfolio.